In Silico Evaluation of Tamarind Leaf Flavonoids Targeting ERα as Anti-Breast Cancer Agents Using Molecular Docking

Azmi Rahmadani, Chintiana Nindya Putri, Anastasya Khoirotul Wachidah, Eva Kholifah

Abstract


Breast cancer particularly the estrogen receptor–positive (ER+) luminal subtype remains a major cause of mortality. Although tamoxifen is the gold-standard therapy, resistance and adverse effects motivate the discovery of new agents. This study identified tamarind (Tamarindus indica L.) leaf flavonoids with potential ERα inhibition using in-silico molecular docking. Twenty-two ethanol-extract compounds were screened by Lipinski’s Rule of Five, docked to ERα (PDB: 1SJ0) with PyRx/AutoDock Vina, and analyzed in Discovery Studio; redocking of the native ligand yielded an RMSD of 0.68 Å, and tamoxifen served as the reference ligand. Four flavonoids exhibited strong ERα binding relative to tamoxifen (−9.1 kcal/mol): apigenin (−9.2), chrysin (−8.9), cynaroside (−8.4), and kaempferol (−8.0), forming stabilizing hydrogen bonds and hydrophobic contacts while largely complying with Lipinski criteria. These findings indicate that tamarind-derived flavonoids—particularly apigenin and chrysin—are promising ERα-targeting candidates and warrant in vitro/in vivo validation for anti-breast cancer development.

Keywords


Tamarindus indica; ERα; Molecular docking; Flavonoids; Breast cancer

Full Text:

PDF

References


M. Shofi, "In silico study of quercetin compounds from purple allamanda leaves (Ruellia tuberosa L.) as anti-breast cancer agents," Jurnal Sintesis, vol. 2, no. 1, pp. 1–9, Aug. 2022. [Online]. Available: https://doi.org/10.56399/jst.v2i1.13

R. M. Shakir, H. N. Jassim, and M. A. Mohammed, "The epidemiology and pathophysiology of breast cancer," International Journal of Health and Medical Research (IJHMR), vol. 3, no. 9, Sept. 2024. [Online]. Available https://doi.org/10.58806/ijhmr.2024.v3i09n02

H. Sung et al., "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, May 2021. [Online]. Available: https://doi.org/10.3322/caac.21660

A. Szymiczek, A. Lone, and M. R. Akbari, "Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review," Clinical Genetics, vol. 99, no. 5, pp. 613–637, May 2021. [Online]. Available: https://doi.org/10.1111/cge.13900

E. Senkus et al., "Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up," Annals of Oncology, vol. 26, suppl. 5, pp. v8–v30, Sept. 2015. [Online]. Available: https://doi.org/10.1093/annonc/mdv298

A. M. Alsughayer et al., "Changing trends in estrogen receptors/progesterone receptors/HER2 prevalence rates among Jordanian patients with breast cancer over the years," JCO Global Oncology, vol. 8, p. e2100359, Mar. 2022. [Online]. Available: https://doi.org/10.1200/GO.21.00359

A. G. Waks and E. P. Winer, "Breast cancer treatment: A review," JAMA, vol. 321, no. 3, pp. 288–300, Jan. 2019. [Online]. Available: https://doi.org/10.1001/jama.2018.19323

L. Ascione, G. Castellano, G. Curigliano, and P. Zagami, "Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives," Current Opinion in Oncology, vol. 36, no. 6, p. 465, Nov. 2024. [Online]. Available: https://doi.org/10.1097/CCO.0000000000001085

R. Jeselsohn et al., "ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer," Nature Reviews Clinical Oncology, vol. 12, no. 10, pp. 573–583, Oct. 2015. [Online]. Available: https://doi.org/10.1038/nrclinonc.2015.117

Y. Gao, Y. Yu, M. Zhang, W. Yu, and L. Kang, "Mechanisms of endocrine resistance in hormone receptor-positive breast cancer," Frontiers in Oncology, vol. 14, Oct. 2024. [Online]. Available: https://doi.org/10.3389/fonc.2024.1448687

N. Dey, P. De, and B. Leyland-Jones, "PI3K–AKT–mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials," Pharmacology & Therapeutics, vol. 175, pp. 91–106, July 2017. [Online]. Available: https://doi.org/10.1016/j.pharmthera.2017.02.037

S. Saji, "Strategies to overcome endocrine resistance," Annals of Oncology, vol. 27, p. vii27, Nov. 2016. [Online]. Available: https://doi.org/10.1093/annonc/mdw473

S. Sumayyah and N. Salsabila, "Traditional medicine: between benefits and side effects," Majalah Farmasetika, vol. 2, no. 5, pp. 1–4, Dec. 2017. [Online]. Available: https://doi.org/10.24198/farmasetika.v2i5.16780

H. Z. Firdausi, S. P. Putri, W. K. Wardani, H. Margasari, and K. Jasmine, "Bioactivity of tamarind (Tamarindus indica L.) leaves," Indonesian Chemistry and Application Journal, vol. 5, no. 2, pp. 77–86, 2022. [Online]. Available: https://doi.org/10.26740/icaj.v5i2.32625

D. Purwaningsih, A. Burhan, A. Awaluddin, and H. Mayangsari, "In vitro test of combined extracts of tamarind leaves (Tamarindus indica L.) and aromatic ginger rhizome (Kaempferia galanga L.) against cancer cells," Medical Science Journal (MS), vol. 7, no. 1, pp. 49–56, Mar. 2022. [Online]. Available: https://doi.org/10.37874/ms.v7i1.273

C. Bhutani, Mansi, P. Khanna, A. Singh, S. Talwar, and L. Khanna, "In silico screening of flavonoids from Cycas as potential aromatase inhibitors for breast cancer therapy and estimation of total flavonoid content and LC–MS analysis of Cycas revoluta extract," Chemistry & Biodiversity, p. e01571, Sept. 2025. [Online]. Available: https://doi.org/10.1002/cbdv.202501571

M. Rajasekar, P. Bhuvanesh, P. Varada, and M. Selvam, "Review on anticancer activity of flavonoid derivatives: Recent developments and future perspectives," Results in Chemistry, vol. 6, p. 101059, Dec. 2023. [Online]. Available: https://doi.org/10.1016/j.rechem.2023.101059

T. T. Eugene-Osoikhia et al., "In silico study of novel dimeric flavonoid (OC251FR2) from the seeds of Garcinia kola Heckel (Clusiaceae) against alpha estrogen receptor (ER-α) of breast cancer," Research Square Preprint, July 2024. [Online]. Available: https://doi.org/10.21203/rs.3.rs-4630579/v1

H. S. Widodo, T. W. Murti, A. Agus, and W. Widodo, "Identification of bioactive angiotensin-converting enzyme inhibitor (ACEi) peptides from β-casein of goat milk polymorphs through in silico technique," Journal of Applied Food Technology, vol. 7, no. 4, Jan. 2019. [Online]. Available: https://doi.org/10.17728/jatp.3008

A. S. Izzaturrahmi et al., "In silico study of licorice (Glycyrrhiza glabra L.) on VEGFR-2 receptor in breast cancer," Indonesian Journal of Biological Pharmacy, vol. 3, no. 3, pp. 137–153, Dec. 2023. [Online]. Available: https://doi.org/10.24198/ijbp.v3i3.45597

S. Dallakyan and A. J. Olson, "Small-molecule library screening by docking with PyRx," Methods in Molecular Biology, vol. 1263, pp. 243–250, 2015. [Online]. Available: https://doi.org/10.1007/978-1-4939-2269-7_19

S. Shamsian, B. Sokouti, and S. Dastmalchi, "Benchmarking different docking protocols for predicting the binding poses of ligands complexed with cyclooxygenase enzymes and screening chemical libraries," Bioimpacts, vol. 14, no. 2, p. 29955, 2024. [Online]. Available: https://doi.org/10.34172/bi.2023.29955

P. F. Ayodele et al., "Illustrated procedure to perform molecular docking using PyRx and Biovia Discovery Studio Visualizer: A case study of 10kt with atropine," Progress in Drug Discovery and Biomedical Science, vol. 6, no. 1, Dec. 2023. [Online]. Available: https://doi.org/10.36877/pddbs.a0000424

M. B. O. Rastini, N. K. M. Giantari, K. D. Adnyani, and N. P. L. Laksmiani, "Molecular docking of anticancer activity of quercetin against breast cancer in silico," Jurnal Kimia (JCHEM), vol. 13, no. 2, p. 180, July 2019. [Online]. Available: https://doi.org/10.24843/jchem.2019.v13.i02.p09

Z. Xiao, S. L. Morris-Natschke, and K.-H. Lee, "Strategies for the optimization of natural leads to anticancer drugs or drug candidates," Medicinal Research Reviews, vol. 36, no. 1, pp. 32–91, Jan. 2016. [Online]. Available: https://doi.org/10.1002/med.21377

A. Daina and V. Zoete, "Application of the SwissDrugDesign online resources in virtual screening," International Journal of Molecular Sciences, vol. 20, no. 18, p. 4612, Sept. 2019. [Online]. Available: https://doi.org/10.3390/ijms20184612

Y. Andhiarto, S. Suciati, E. N. Praditapuspa, and S. Sukardiman, "In silico analysis and ADMET prediction of flavonoid compounds from Syzygium cumini var. album on α-glucosidase receptor for anti-diabetic drug candidates," Pharmacognosy Journal, vol. 14, no. 6, pp. 736–743, Jan. 2023. [Online]. Available: https://doi.org/10.5530/pj.2022.14.161

S. Vittorio et al., "Addressing docking pose selection with structure-based deep learning: Recent advances, challenges and opportunities," Computational and Structural Biotechnology Journal, vol. 23, pp. 2141–2151, Dec. 2024. [Online]. Available: https://doi.org/10.1016/j.csbj.2024.05.024

N. Effendi, N. A. Saputri, H. Purnomo, and A. Aminah, "In silico ADME–T and molecular docking of tamoxifen analogs as potential anti-breast cancer agents," Media Farmasi, vol. 19, no. 1, Apr. 2023. [Online]. Available: https://doi.org/10.32382/mf.v19i1.3305

Q. Xue et al., "Evaluation of the binding performance of flavonoids to estrogen receptor alpha by AutoDock, AutoDock Vina and Surflex-Dock," Ecotoxicology and Environmental Safety, vol. 233, p. 113323, Mar. 2022. [Online]. Available: https://doi.org/10.1016/j.ecoenv.2022.113323

T. H. Pham et al., "Apigenin, a partial antagonist of the estrogen receptor (ER), inhibits ER-positive breast cancer cell proliferation through Akt/FOXM1 signaling," International Journal of Molecular Sciences, vol. 22, no. 1, p. 470, Jan. 2021. [Online]. Available: https://doi.org/10.3390/ijms22010470

I. Bisaria et al., "The effect of chrysin binding on the conformational dynamics and unfolding pathway of human serum albumin," Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 316, p. 124332, Aug. 2024. [Online]. Available: https://doi.org/10.1016/j.saa.2024.124332

H. Riasari, R. Rachmaniar, and S. Wahyuni, "Evaluation patch of rhizome extract of Kaempferia galanga L. as anti-inflammatory with enhancer," Indonesian Journal of Pharmaceutical Science and Technology, vol. 6, no. 2, pp. 59–64, June 2019. [Online]. Available: https://doi.org/10.24198/ijpst.v6i2.18932

T. Wang et al., "The interaction of isoflavone phytoestrogens with ERα and ERβ by molecular docking and molecular dynamics simulations," Current Computer-Aided Drug Design, vol. 17, no. 5, pp. 655–665, 2021. [Online]. Available: https://doi.org/10.2174/1573409916666200712140245

S. Islam et al., "Integrating computational 3D-QSAR and pharmacophore modelling in diverse natural phytochemical libraries for targeted therapy against breast cancer estrogen receptors," Next Research, vol. 1, no. 1, p. 100012, Oct. 2024. [Online]. Available: https://doi.org/10.1016/j.nexres.2024.100012

K. Rajagopal et al., "Identifying potent breast cancer inhibitors against ERα target using pharmacophore model, 3D-QSAR and MD studies," ChemistrySelect, vol. 9, no. 32, p. e202401099, 2024. [Online]. Available: https://doi.org/10.1002/slct.202401099




DOI: https://doi.org/10.37311/ijpe.v5i3.33673

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Azmi Rahmadani, Chintiana Nindya Putri, Anastasya Khoirotul, Eva Kholifah

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.